Persistence of Oral DNA Adducts in Smokers and Vapers
Launched by UNIVERSITY OF MINNESOTA · May 13, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of smoking and vaping on oral health, specifically how they might damage cells in the mouth and potentially lead to oral cancer. Researchers want to compare the levels of DNA damage in three groups of people: those who smoke every day, those who vape every day, and those who have never used tobacco or nicotine products. By looking at these differences, they hope to find out which types of damage are more likely to contribute to cancer.
To participate in this study, you need to be at least 21 years old and in good physical and mental health. You could be eligible if you smoke or vape daily or if you do not use any tobacco products at all. However, if you are pregnant, nursing, have high blood pressure, or a history of certain health conditions, you may not qualify. If you join the study, you will help researchers learn more about the long-term effects of smoking and vaping on oral health, which is important for preventing cancer in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 21+ years old
- • Good physical and mental health
- • Stable physical and mental health
- • Either 1) smokes cigarettes daily, 2) vapes daily, 3) does not use any tobacco or nicotine products
- Exclusion Criteria:
- • Pregnant or nursing
- • High blood pressure
- • Unstable health condition(s)
- • History of cancer or liver disease
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Stephen Hecht
Principal Investigator
University of Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported